Literature DB >> 3289620

Interdomain cleavage of plasma fibronectin by zinc-metalloproteinase from Serratia marcescens.

A Molla1, S Tanase, Y M Hong, H Maeda.   

Abstract

Limited proteolysis of porcine plasma fibronectin by the 56 kDa proteinase (56K proteinase) (EC 3.4.24.4) from Serratia marcescens released six polypeptides: a 27 kDa peptide, the heparin-binding domain which comprises the NH2-terminal end; a 50 kDa peptide, a mid-molecule that mediates binding to gelatin or collagen; a 160 kDa peptide, that contained the heparin-binding domain with cell-spreading activity; and a 140 and a 20 kDa peptide which released from the 160 kDa peptide. Each fragment was purified and characterized by its chemical and biological properties, and it was found that they were respectively different domains. Both the 160 and the 140 kDa peptide contained one cysteine per mole of peptide. The 160 kDa peptides were connected by a 6 kDa peptide, which was present at the COOH-terminal end of the molecule and was biologically inactive. Only 6 kDa peptide contained a disulfide bond and produced 3 kDa peptide after reduction, whereas other fragments did not change with or without reduction on SDS-polyacrylamide gel electrophoresis. NH2-terminal sequence analyses of the released peptides showed that the 56K proteinase cleaved the fibronectin between the Arg-Thr (located at two different sites), Leu-Ser and Gln-Glu bonds. Out of 118 Arg residues, there are nine sequences containing Arg-Thr, and two of them near or at an interdomain location (at Arg 259 and 2239) were cleaved. Out of 124 Leu residues, there are 11 Leu-Ser sequences and only one, at 687, was cleaved. The above fragments with functional domain activity could be aligned according to the previously reported amino-acid sequence of human or bovine plasma fibronectin. The treatment of fibroblast cells by the 56K proteinase resulted in loss of morphological integrity and extracellular matrix.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3289620     DOI: 10.1016/0167-4838(88)90181-1

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  7 in total

1.  Inactivation of various proteinase inhibitors and the complement system in human plasma by the 56-kilodalton proteinase from Serratia marcescens.

Authors:  A Molla; T Akaike; H Maeda
Journal:  Infect Immun       Date:  1989-06       Impact factor: 3.441

2.  Metalloproteases of infective Ancylostoma hookworm larvae and their possible functions in tissue invasion and ecdysis.

Authors:  P Hotez; J Haggerty; J Hawdon; L Milstone; H R Gamble; G Schad; F Richards
Journal:  Infect Immun       Date:  1990-12       Impact factor: 3.441

3.  Therapeutic intervention with chicken egg white ovomacroglobulin and a new quinolone on experimental Pseudomonas keratitis.

Authors:  S Miyagawa; R Kamata; K Matsumoto; R Okamura; H Maeda
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1994-08       Impact factor: 3.117

4.  Inhibitory effects of ovomacroglobulin on bacterial keratitis in rabbits.

Authors:  S Miyagawa; R Kamata; K Matsumoto; R Okamura; H Maeda
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1991       Impact factor: 3.117

5.  Identification of Porphyromonas gingivalis components that mediate its interactions with fibronectin.

Authors:  M S Lantz; R D Allen; L W Duck; J L Blume; L M Switalski; M Hook
Journal:  J Bacteriol       Date:  1991-07       Impact factor: 3.490

6.  Molecular mechanism of complex infection by bacteria and virus analyzed by a model using serratial protease and influenza virus in mice.

Authors:  T Akaike; A Molla; M Ando; S Araki; H Maeda
Journal:  J Virol       Date:  1989-05       Impact factor: 5.103

7.  Identification of a novel zinc metalloprotease through a global analysis of Clostridium difficile extracellular proteins.

Authors:  Valeria Cafardi; Massimiliano Biagini; Manuele Martinelli; Rosanna Leuzzi; Jeffrey T Rubino; Francesca Cantini; Nathalie Norais; Maria Scarselli; Davide Serruto; Meera Unnikrishnan
Journal:  PLoS One       Date:  2013-11-26       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.